araag2/HINT huggingface dataset:
Clinical trial NCT00662675 (phase 3, status: completed)
Conditions: exocrine pancreatic insufficiency, steatorrhea, malabsorption syndromes, cystic fibrosis
ICD codes: K86.81, K90.3, K90.89, K90.9, K91.2, M83.2, K90.49, D51.1, E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: pancrease mt 10.5, or mt 21, placebo for pancrease mt 10.5 or mt 21
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a diagnosis of CF documented by sweat chloride results (>60 mmol/L) and require
             pancreatic enzyme replacement therapy (PERT) to control clinical symptoms of EPI
             (nausea, vomiting, bloating, diarrhea, and abdominal pain) with a history of excess
             fat in the feces

          -  Have documentation of an abnormal COA-fat and a fecal elastase result of <100
             micrograms fecal elastase/gram stool

          -  Must be on a stable diet and dose of pancreatic enzyme supplementation that has
             provided satisfactory symptom control for at least the past 1 month

        Exclusion Criteria:

          -  No extreme physical wasting with loss of weight and muscle mass

          -  No severe, acute, or chronic pulmonary disease unrelated to complications of CF

          -  No worsening of pulmonary disease in past 30 days

          -  No use of drugs known to affect blood uric acid concentrations (e.g., aspirin,
             diflunisal, allopurinol, probenecid, thiazide diuretics, phenylbutazone,
             sulfinpyrazone)

          -  No known congenital (present at birth) abnormalities of the gastrointestinal tract,
             heart, or liver

          -  No distal intestinal obstruction syndrome (DIOS)
Clinical trial NCT00712920 (phase 3, status: completed)
Conditions: perennial allergic rhinitis
ICD codes: D69.0, L50.0, B44.81, J30.89, J30.9, L20.84, H10.45
Drugs: 0.15% azelastine hydrochloride, 0.1% azelastine hydrochloride, placebo
SMILES: CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=CC=CC=C2C1=O, CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=CC=CC=C2C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients 12 years of age and older

          -  Must be in generally good health

          -  Must meet minimum symptom requirements, as specified in protocol

          -  Must be willing and able to provide informed consent and participate in all study
             procedures

          -  2-year history of PAR

          -  Positive skin test to cockroach, dust mite, mold or cat/dog dander

        Exclusion Criteria:

          -  On nasal examination, presence of any nasal mucosal erosion, nasal ulceration or nasal
             septal perforation at the screening or randomization visit

          -  Nasal diseases likely to affect deposition of intranasal medication, such as
             sinusitis, rhinitis medicamentosa, significant polyposis or nasal structural
             abnormalities

          -  Nasal surgery or sinus surgery within the previous year

          -  The use of any investigational drug within 30 days

          -  Presence of any hypersensitivity to drugs similar to azelastine and to either sorbitol
             or sucralose

          -  Women who are pregnant or nursing

          -  Women of child-bearing potential who are not abstinent and not practicing a medically
             acceptable method of contraception

          -  Respiratory tract infection within 2 weeks of screening

          -  Respiratory tract infections requiring oral antibiotic treatment within 2 weeks of
             screening

          -  Patients with asthma with the exception of mild, intermittent

          -  Significant pulmonary disease including COPD

          -  Patients with arrhythmia

          -  Patients with a known history of alcohol or drug abuse

          -  Existence of any surgical or medical condition, which in the opinion of the
             investigator or sponsor may significantly alter the absorption, distribution,
             metabolism or excretion of study drug.

          -  Clinically relevant abnormal physical findings within one week of randomization

          -  Overnight abscences from home for more than 3 nights

          -  Employees of the research center or private practice and family members are excluded

          -  Patients who received prohibited medications within specified timepoints in protocol.
Clinical trial NCT00210782 (phase 3, status: completed)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: topiramate, phenytoin
SMILES: O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Seizures indicative of new-onset epilepsy (or epilepsy relapse) of untreated epilepsy

          -  at least one but not more than 20 unprovoked seizures within past 3 months

          -  weighing more than 110 pounds

          -  considered to be a good candidate for rapid initiation of anti-seizure medication

          -  able to swallow a tablet whole (without crushing it).

        Exclusion Criteria:

          -  Not having taken anti-seizure medications within the past 30 days

          -  no provoking factors for seizures (presence of alcohol withdrawal, drug intoxication,
             acute meningitis or encephalitis, acute head injury or stroke, acute hypoxic/ischemic
             encephalopathy, or brain tumor)

          -  no presence of active liver disease or serious kidney disease

          -  not pregnant or breast-feeding

          -  not using birth control.
Clinical trial NCT01388361 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec, insulin aspart, liraglutide
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities. (Trial-related
             activities are any procedure that would not have been performed during normal
             management of the subject).

          -  The subject must have completed the end of treatment visit of NN1250-3643 with Insulin
             degludec once daily + metformin.

          -  Ability and willingness to adhere to the protocol including self measurement of plasma
             glucose according to the protocol

        Exclusion Criteria:

          -  Participated in NN1250-3643 and treated with insulin glargine

          -  Previous treatment with glucacon like peptide (GLP-1) receptor agonists (e.g.
             exenatide, liraglutide)

          -  Impaired liver function, defined as alanine aminotransferase (ALAT) 2.5 times the
             upper limit of normal at end of treatment in NN1250-3643

          -  Impaired renal function defined as serum-creatinine = 125 µmol/l (= 1.4 mg/dl) for
             males and = 110 µmol/L (= 1.3 mg/dl) for females or according to local label for
             metformin [For France: glomerular filtration rate below 60 ml/min, calculated by the
             Cockroft & Gault formula] at end of treatment in NN1250-3643.
Clinical trial NCT00442338 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: montelukast sodium, montelukast sodium, aminophylline hydrate
SMILES: [H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult participants with acute asthma attacks

        Exclusion Criteria:

          -  Participant has any known or suspected, acute or chronic cause for their pulmonary
             symptoms other than asthma (e.g., COPD, chronic heart failure, etc.).

          -  Participant has a smoking habit (15 cigarettes per day) within a month prior to
             screening period, and/or has a smoking history (20 cigarettes per day) of more than 15
             years.

          -  Participant has a disease of the cardiovascular, hepatic, renal, hematologic systems,
             or other severe disease.
Clinical trial NCT00003636 (phase 3, status: completed)
Conditions: fallopian tube cancer, ovarian cancer, primary peritoneal cavity cancer
ICD codes: C57.00, C57.01, C57.02, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C30.0, Z12.81, D14.0, C14.8, D37.09, Z86.003, Z85.818
Drugs: carboplatin, cisplatin
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically proven stage IIIC or IV ovarian epithelial carcinoma, peritoneal
             carcinoma, or fallopian tube carcinoma

               -  If biopsy is not available, evidence of adenocarcinoma by fine needle aspiration
                  allowed if all of the following are true:

                    -  Presence of pelvic ovarian mass

                    -  Omental cake or other metastasis larger than 2 cm in the upper abdomen
                       and/or regional lymph node metastasis

                    -  CA 125/carcinoembryonic antigen ratio greater than 25 (if ratio less than
                       25, barium enema or colonoscopy AND gastroscopy or radiological examination
                       of the stomach must be negative for primary tumor)

                    -  Normal mammography (if CA 125/carcinoembryonic antigen ratio less than 25)

          -  Tumor greater than 2 cm, excluding ovaries, on laparoscopy or CT scan

          -  No brain or leptomeningeal metastases

        PATIENT CHARACTERISTICS:

        Age:

          -  Not specified

        Performance status:

          -  WHO 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC greater than 3,000/mm^3

          -  Platelet count greater than 100,000/mm^3

        Hepatic:

          -  Bilirubin less than 1.25 times upper limit of normal (ULN)

        Renal:

          -  Creatinine less than 1.25 times ULN

        Other:

          -  No other serious disabling diseases contraindicating primary cytoreductive surgery or
             primary platin-based chemotherapy

          -  No other prior primary malignancies except carcinoma in situ of the cervix or basal
             cell carcinoma of the skin

          -  No psychological, familial, sociological, or geographical condition potentially
             preventing protocol compliance or follow-up

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  No other prior procedures except diagnostic biopsy by laparotomy or laparoscopy
Clinical trial NCT00502840 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: rituximab [mabthera/rituxan]
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients with rheumatoid arthritis who participated in ML19070, and have
             completed the week 24 visit;

          -  eligible for re-treatment (DAS28 >2.6 after week 24, swollen joint count >=4, tender
             joint count >=4).

        Exclusion Criteria:

          -  patients who have withdrawn from treatment in ML19070 pre-week 16;

          -  patients with a previous response in DAS28 <0.6 to MabThera after week 16;

          -  concurrent treatment with any DMARD except for methotrexate, any TNF alpha inhibitor,
             or other biologic or investigational agent.
Clinical trial NCT01436071 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: fluticasone furoate 50mcg, placebo
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent

          -  Outpatient at least 12 years of age with diagnosis of asthma at least 12 weeks before
             first visit

          -  Both genders; females of child bearing potential must be willing to use appropriate
             contraception during the study

          -  Pre-bronchodilator FEV1 of at least 60% predicted

          -  FEV1 reversibility of at least 12% and 200mls

          -  Current asthma therapy that includes a non-corticosteroid controller and/or
             short-acting beta agonist

        Exclusion Criteria:

          -  History of life-threatening asthma exacerbation within the past 10 years

          -  Asthma exacerbation requiring treatment with oral corticosteroids within the last 3
             months or that required overnight hospital stay within 6 months

          -  Current or recent respiratory infection or current oral candida infection

          -  Presence of another significant respiratory disease or medical condition that is not
             controlled or that could affect subject safety or study outcome

          -  Known or suspected allergy to study drug or materials

          -  Taking another investigational medication or prohibited medication during the study

          -  Previous treatment with inhaled fluticasone furoate in a phase II or III study

          -  Current smokers or former smokers with significant tobacco exposure

          -  Children in Care
Clinical trial NCT00162734 (phase 3, status: completed)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: daily infergen (interferon alfacon-1, cifn) (9 or 15 µg) + ribavirin (1000-1200 mg, based on body weight) po daily for up to 48 wks
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        (Abbreviated due to space constraints.)

        Inclusion Criteria:

          1. Signed informed consent form

          2. Previously randomized to the No-Treatment Arm in IRHC-001 protocol

          3. IRHC-001 no-treatment patients ho have either < 2 log10 reduction in plasma HCV RNA
             level by bDNA assay at Week 24 compared to baseline or detectable plasma HCV RNA by
             bDNA or TMA assays at Week 48

          4. All patients and all potentially fertile sexual partners of patients must use 2
             reliable forms of effective contraception during the study & for 6 months after
             cessation of the study drugs

        Exclusion Criteria:

          1. Patients who experienced hepatic decompensation during IRHC-001 or show laboratory,
             clinical, or physiologic evidence of hepatic decompensation at screening for IRHC-002

          2. Patients who, in the opinion of the Investigator or the Sponsor, are not suitable
             candidates for enrollment or who would not comply w/the requirements of the study

          3. Pregnant or lactating women

          4. Male partners of women who are pregnant

          5. Patients who were on any experimental protocols or therapy while participating in
             IRHC-001
Clinical trial NCT00061815 (phase 3, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: oxaliplatin, leucovorin, 5-fluorouracil, 5-fluorouracil
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, FC1=CNC(=O)NC1=O, FC1=CNC(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Documented colorectal cancer which is EGFR-positive and is metastatic.

          -  Prior irinotecan, alone or in combination, as first-line treatment of metastatic
             disease.

        Exclusion Criteria:

          -  A serious uncontrolled medical disorder that, in the opinion of the Investigator,
             would impair the ability of the subject to receive protocol therapy.

          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency.

          -  Known metastases in the central nervous system.

          -  Symptomatic sensory or peripheral neuropathy.

          -  More than one prior chemotherapy regimen for the treatment of metastatic colorectal
             cancer.

          -  Prior oxaliplatin therapy.

          -  Prior cetuximab or other therapy which targets the EGF pathway.

          -  Prior chimerized or murine monoclonal antibody therapy.
Clinical trial NCT00645190 (phase 3, status: completed)
Conditions: alzheimer disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: galantamine hbr
SMILES: [H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3
Eligibility criteria:

        Inclusion Criteria:

          -  Out-patients diagnosed with mild to moderate probable AD. The diagnosis should have
             been established in accordance with the classification for probable AD of NINCDS-ADRDA

          -  MMSE score of 10-24 (inclusive) at screening

          -  Patients who lived with or had regular daily visits from a responsible caregiver

          -  .Has signed the informed consent form by subject and assent form by care-giver

        Exclusion Criteria:

          -  Patients with neurodegenerative disorders such as Parkinson's disease

          -  Patients with some conditions possibly resulting in cognitive impairment, e.g. acute
             cerebral trauma, infection

          -  Has evidence of multi-infarct dementia or clinically active cerebrovascular disease.
Clinical trial NCT00098137 (phase 3, status: completed)
Conditions: heart disease, arrhythmia, atrial fibrillation
ICD codes: I11.0, I11.9, I27.1, I51.9, I09.9, I27.9, I01.8, I49.9, I47.0, I49.8, I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: olmesartan
SMILES: CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O
Eligibility criteria:

        Inclusion Criteria:

          -  Documented paroxysmal atrial fibrillation: ECG documentation of atrial fibrillation at
             least in one ECG recorded during the last 2 months prior to randomization plus
             additional ECG recording of sinus rhythm at least 12 hours after the above mentioned
             ECG documentation.

          -  Age ≥ 18

          -  Patient informed orally and in writing

          -  Written informed consent of the patient

        Exclusion Criteria:

          -  Strong clinical evidence for therapy with AT II/ACE inhibitors

          -  AT II/ACE inhibitor therapy within the last month

          -  Therapy with antiarrhythmic agents of class I or class III within the last month,
             therapy with amiodarone within the last 3 months

          -  Direct current (DC) cardioversion within the last 3 months

          -  Symptomatic bradycardia

          -  Implanted pacemaker or implanted cardioverter/defibrillator with any antitachycardiac
             algorithm in use

          -  Cardiac surgery or cardiac catheter ablation within the last 3 months

          -  Typical angina pectoris symptoms at rest or during exercise

          -  Known coronary artery disease with indication for intervention

          -  Valvular disease > II degree

          -  Left ventricular ejection fraction < 40%

          -  Diastolic blood pressure > 110mm Hg at rest

          -  Symptomatic arterial hypotension

          -  Known renal artery stenosis

          -  Serum creatinine > 1.8 mval/l

          -  Relevant hepatic or pulmonary disorders

          -  Hyperthyroidism manifested clinically and in laboratory

          -  Known drug intolerance for AT II inhibitors

          -  Females who are pregnant or breast feeding

          -  Females of childbearing potential who are not using a scientifically accepted method
             of contraception

          -  Participation in a clinical trial within the last 30 days

          -  Drug addiction or chronic alcohol abuse

          -  Legal incapacity, or other circumstances which would prevent the patient from
             understanding the aim, nature or extent of the clinical study

          -  Evidence of an uncooperative attitude
Clinical trial NCT01484119 (phase 3, status: completed)
Conditions: seasonal allergic rhinitis
ICD codes: J30.2
Drugs: act-129968, placebo, cetirizine
SMILES: OC(=O)CN1C2=C(CN(CC2)C(=O)C2=CC=CC3=CC=CC=C23)C2=CC(F)=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Eligibility criteria:

        Inclusion Criteria

          -  Males and females aged 12-76 years with documented clinical history of symptomatic
             seasonal allergic rhinitis associated with mountain cedar pollen for the last 2 years.

          -  Evening reflective Total Nasal Symptom Score (p.m.rTNSS) at least 42 out of a maximum
             potential score of 84 over the 7-day run-in period, or > or = 6 out of a maximum score
             of 12 on each of the last 4 consecutive days during the run-in period.

        Exclusion Criteria

          -  Non-allergic rhinitis.

          -  Severe physical nasal obstruction.

          -  Acute or significant chronic sinusitis.

          -  Bacterial or viral infection of the upper or lower respiratory tract, nasal sinuses,
             or middle ear.

          -  Ongoing chronic respiratory disorders.

          -  Asthma requiring use of short-acting beta2-agonists > 2 times a week or any asthma
             treatment other than inhaled short-acting beta2-agonists.

          -  Diagnosis of aspirin or non-steroidal anti-inflammatory drug (NSAID)-induced asthma.

          -  Nasal biopsy or surgery, sinus surgery, or perforation within the 8 weeks prior to the
             Screening Visit.

          -  Ocular surgery within the 8 weeks prior to the Screening Visit.

          -  Ocular infections (bacterial or viral) within the 4 weeks before screening.

          -  Use of forbidden medications (prescribed or over-the-counter [OTC])

          -  Congenital or acquired severe immunodeficiency or known Human immunodeficiency virus
             (HIV)infection.